Biosimilar to Xolair® (omalizumab)

About Teva

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a dual strategy of being a generics/biosimilars powerhouse and an innovative specialty medicines developer. Its mission, 'We are all in for better health,' is executed through a focus on neuroscience and immunology, leveraging strategic partnerships and a robust pipeline. The company is currently in the 'Acceleration Phase' of its 'Pivot to Growth' plan, aiming for consistent financial performance and pipeline execution, having delivered three consecutive years of growth as of 2025.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is executing a successful 'Pivot to Growth' strategy, transitioning from a generics-centric model to an innovation-driven biopharmaceutical company. This shift has yielded three consecutive years of revenue growth, driven by its specialty portfolio in CNS disorders and a burgeoning biosimilars pipeline. The company's integrated model, spanning complex generics, API manufacturing, and novel drug development, provides a durable competitive moat and positions it to address both affordability and unmet medical needs globally.

Therapeutic Areas